Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 2002 Nov 15;368(Pt 1):325–332. doi: 10.1042/BJ20020494

Impaired 2',3'-dideoxy-3'-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11.

O Turriziani 1, J D Schuetz 1, F Focher 1, C Scagnolari 1, J Sampath 1, M Adachi 1, F Bambacioni 1, E Riva 1, G Antonelli 1
PMCID: PMC1222956  PMID: 12133003

Abstract

Cellular factors may contribute to the decreased efficacy of chemotherapy in HIV infection. Indeed, prolonged treatment with nucleoside analogues, such as azidothymidine (AZT), 2',3'-deoxycytidine or 9-(2-phosphonylmethoxyethyl)adenine, induces cellular resistance. We have developed a human T lymphoblastoid cell line (CEM 3TC) that is selectively resistant to the antiproliferative effect of 2',3'-dideoxy-3'-thiacytidine (3TC) because the CEM 3TC cells were equally sensitive to AZT, as well as the antimitotic agent, vinblastine. The anti-retroviral activity of 3TC against HIV-1 was also severely impaired in the CEM 3TC cells. Despite similar deoxycytidine kinase activity and unchanged uptake of nucleosides such as AZT and 2'-deoxycytidine, CEM 3TC had profoundly impaired 3TC accumulation. Further studies indicated that CEM 3TC retained much less 3TC. However, despite a small overexpression of multidrug resistance protein (MRP) 4, additional studies with cells specifically engineered to overexpress MRP4 demonstrated there was no impact on either 3TC accumulation or efflux. Finally, an increased expression of the MRP5 homologue, ATP-binding cassette C11 (ABCC11) was observed in the CEM 3TC cells. We speculate that the decreased 3TC accumulation in the CEM 3TC might be due to the upregulation of ABCC11.

Full Text

The Full Text of this article is available as a PDF (210.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antonelli G., Turriziani O., Cianfriglia M., Riva E., Dong G., Fattorossi A., Dianzani F. Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein. AIDS Res Hum Retroviruses. 1992 Oct;8(10):1839–1844. doi: 10.1089/aid.1992.8.1839. [DOI] [PubMed] [Google Scholar]
  2. Antonelli G., Turriziani O., Verri A., Narciso P., Ferri F., D'Offizi G., Dianzani F. Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase. AIDS Res Hum Retroviruses. 1996 Feb 10;12(3):223–228. doi: 10.1089/aid.1996.12.223. [DOI] [PubMed] [Google Scholar]
  3. Avramis V. I., Kwock R., Solorzano M. M., Gomperts E. Evidence of in vitro development of drug resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection. J Acquir Immune Defic Syndr. 1993 Dec;6(12):1287–1296. [PubMed] [Google Scholar]
  4. Borst P., Evers R., Kool M., Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000 Aug 16;92(16):1295–1302. doi: 10.1093/jnci/92.16.1295. [DOI] [PubMed] [Google Scholar]
  5. Bradley G., Juranka P. F., Ling V. Mechanism of multidrug resistance. Biochim Biophys Acta. 1988 Aug 3;948(1):87–128. doi: 10.1016/0304-419x(88)90006-6. [DOI] [PubMed] [Google Scholar]
  6. Cameron D. W., Japour A. J., Xu Y., Hsu A., Mellors J., Farthing C., Cohen C., Poretz D., Markowitz M., Follansbee S. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS. 1999 Feb 4;13(2):213–224. doi: 10.1097/00002030-199902040-00009. [DOI] [PubMed] [Google Scholar]
  7. Cass C. E., Young J. D., Baldwin S. A., Cabrita M. A., Graham K. A., Griffiths M., Jennings L. L., Mackey J. R., Ng A. M., Ritzel M. W. Nucleoside transporters of mammalian cells. Pharm Biotechnol. 1999;12:313–352. doi: 10.1007/0-306-46812-3_12. [DOI] [PubMed] [Google Scholar]
  8. Chang C. N., Skalski V., Zhou J. H., Cheng Y. C. Biochemical pharmacology of (+)- and (-)-2',3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents. J Biol Chem. 1992 Nov 5;267(31):22414–22420. [PubMed] [Google Scholar]
  9. Denizot F., Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986 May 22;89(2):271–277. doi: 10.1016/0022-1759(86)90368-6. [DOI] [PubMed] [Google Scholar]
  10. Dianzani F., Antonelli G., Turriziani O., Riva E., Simeoni E., Signoretti C., Strosselli S., Cianfriglia M. Zidovudine induces the expression of cellular resistance affecting its antiviral activity. AIDS Res Hum Retroviruses. 1994 Nov;10(11):1471–1478. doi: 10.1089/aid.1994.10.1471. [DOI] [PubMed] [Google Scholar]
  11. Durant J., Clevenbergh P., Halfon P., Delgiudice P., Porsin S., Simonet P., Montagne N., Boucher C. A., Schapiro J. M., Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999 Jun 26;353(9171):2195–2199. doi: 10.1016/s0140-6736(98)12291-2. [DOI] [PubMed] [Google Scholar]
  12. Finzi D., Hermankova M., Pierson T., Carruth L. M., Buck C., Chaisson R. E., Quinn T. C., Chadwick K., Margolick J., Brookmeyer R. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997 Nov 14;278(5341):1295–1300. doi: 10.1126/science.278.5341.1295. [DOI] [PubMed] [Google Scholar]
  13. Fridland A., Connelly M. C., Ashmun R. Relationship of deoxynucleotide changes to inhibition of DNA synthesis induced by the antiretroviral agent 3'-azido-3'-deoxythymidine and release of its monophosphate by human lymphoid cells (CCRF-CEM). Mol Pharmacol. 1990 May;37(5):665–670. [PubMed] [Google Scholar]
  14. Fridland A., Connelly M. C., Robbins B. L. Cellular factors for resistance against antiretroviral agents. Antivir Ther. 2000 Sep;5(3):181–185. [PubMed] [Google Scholar]
  15. Gollapudi S., Gupta S. Human immunodeficiency virus I-induced expression of P-glycoprotein. Biochem Biophys Res Commun. 1990 Sep 28;171(3):1002–1007. doi: 10.1016/0006-291x(90)90783-j. [DOI] [PubMed] [Google Scholar]
  16. Gottesman Michael M., Fojo Tito, Bates Susan E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002 Jan;2(1):48–58. doi: 10.1038/nrc706. [DOI] [PubMed] [Google Scholar]
  17. Gröschel B., Cinatl J., Cinatl J., Jr Viral and cellular factors for resistance against antiretroviral agents. Intervirology. 1997;40(5-6):400–407. doi: 10.1159/000150572. [DOI] [PubMed] [Google Scholar]
  18. Gulick R. M., Mellors J. W., Havlir D., Eron J. J., Gonzalez C., McMahon D., Jonas L., Meibohm A., Holder D., Schleif W. A. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA. 1998 Jul 1;280(1):35–41. doi: 10.1001/jama.280.1.35. [DOI] [PubMed] [Google Scholar]
  19. Gulick R. M., Mellors J. W., Havlir D., Eron J. J., Gonzalez C., McMahon D., Richman D. D., Valentine F. T., Jonas L., Meibohm A. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997 Sep 11;337(11):734–739. doi: 10.1056/NEJM199709113371102. [DOI] [PubMed] [Google Scholar]
  20. Günthard H. F., Wong J. K., Ignacio C. C., Guatelli J. C., Riggs N. L., Havlir D. V., Richman D. D. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol. 1998 Mar;72(3):2422–2428. doi: 10.1128/jvi.72.3.2422-2428.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lecureur V., Sun D., Hargrove P., Schuetz E. G., Kim R. B., Lan L. B., Schuetz J. D. Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24–35. [PubMed] [Google Scholar]
  22. Litman T., Brangi M., Hudson E., Fetsch P., Abati A., Ross D. D., Miyake K., Resau J. H., Bates S. E. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci. 2000 Jun;113(Pt 11):2011–2021. doi: 10.1242/jcs.113.11.2011. [DOI] [PubMed] [Google Scholar]
  23. Lostao M. P., Mata J. F., Larrayoz I. M., Inzillo S. M., Casado F. J., Pastor-Anglada M. Electrogenic uptake of nucleosides and nucleoside-derived drugs by the human nucleoside transporter 1 (hCNT1) expressed in Xenopus laevis oocytes. FEBS Lett. 2000 Sep 15;481(2):137–140. doi: 10.1016/s0014-5793(00)01983-9. [DOI] [PubMed] [Google Scholar]
  24. Magnani M., Brandi G., Casabianca A., Fraternale A., Schiavano G. F., Rossi L., Chiarantini L. 2',3'-Dideoxycytidine metabolism in a new drug-resistant cell line. Biochem J. 1995 Nov 15;312(Pt 1):115–123. doi: 10.1042/bj3120115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Martinez-Picado J., DePasquale M. P., Kartsonis N., Hanna G. J., Wong J., Finzi D., Rosenberg E., Gunthard H. F., Sutton L., Savara A. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10948–10953. doi: 10.1073/pnas.97.20.10948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. O'Brien W. A. Resistance against reverse transcriptase inhibitors. Clin Infect Dis. 2000 Jun;30 (Suppl 2):S185–S192. doi: 10.1086/313858. [DOI] [PubMed] [Google Scholar]
  27. Perrin L., Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science. 1998 Jun 19;280(5371):1871–1873. doi: 10.1126/science.280.5371.1871. [DOI] [PubMed] [Google Scholar]
  28. Robbins B. L., Connelly M. C., Marshall D. R., Srinivas R. V., Fridland A. A human T lymphoid cell variant resistant to the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine shows a unique combination of a phosphorylation defect and increased efflux of the agent. Mol Pharmacol. 1995 Feb;47(2):391–397. [PubMed] [Google Scholar]
  29. Schuetz J. D., Connelly M. C., Sun D., Paibir S. G., Flynn P. M., Srinivas R. V., Kumar A., Fridland A. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med. 1999 Sep;5(9):1048–1051. doi: 10.1038/12487. [DOI] [PubMed] [Google Scholar]
  30. Spadari S., Maga G., Verri A., Focher F. Molecular basis for the antiviral and anticancer activities of unnatural L-beta-nucleosides. Expert Opin Investig Drugs. 1998 Aug;7(8):1285–1300. doi: 10.1517/13543784.7.8.1285. [DOI] [PubMed] [Google Scholar]
  31. Srinivas R. V., Connely M., Fridland A. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) inhibits HIV-1 replication in epithelial cells, but not T-lymphocytes. Antiviral Res. 1997 Jun;35(1):23–27. doi: 10.1016/s0166-3542(97)01035-8. [DOI] [PubMed] [Google Scholar]
  32. Tammur J., Prades C., Arnould I., Rzhetsky A., Hutchinson A., Adachi M., Schuetz J. D., Swoboda K. J., Ptácek L. J., Rosier M. Two new genes from the human ATP-binding cassette transporter superfamily, ABCC11 and ABCC12, tandemly duplicated on chromosome 16q12. Gene. 2001 Jul 25;273(1):89–96. doi: 10.1016/s0378-1119(01)00572-8. [DOI] [PubMed] [Google Scholar]
  33. Turriziani O., Antonelli G., Dianzani F. Cellular factors involved in the induction of resistance of HIV to antiretroviral agents. Int J Antimicrob Agents. 2000 Nov;16(3):353–356. doi: 10.1016/s0924-8579(00)00264-8. [DOI] [PubMed] [Google Scholar]
  34. Verri A., Focher F., Priori G., Gosselin G., Imbach J. L., Capobianco M., Garbesi A., Spadari S. Lack of enantiospecificity of human 2'-deoxycytidine kinase: relevance for the activation of beta-L-deoxycytidine analogs as antineoplastic and antiviral agents. Mol Pharmacol. 1997 Jan;51(1):132–138. doi: 10.1124/mol.51.1.132. [DOI] [PubMed] [Google Scholar]
  35. Wijnholds J., Mol C. A., van Deemter L., de Haas M., Scheffer G. L., Baas F., Beijnen J. H., Scheper R. J., Hatse S., De Clercq E. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7476–7481. doi: 10.1073/pnas.120159197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Wong J. K., Hezareh M., Günthard H. F., Havlir D. V., Ignacio C. C., Spina C. A., Richman D. D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997 Nov 14;278(5341):1291–1295. doi: 10.1126/science.278.5341.1291. [DOI] [PubMed] [Google Scholar]
  37. Yabuuchi H., Shimizu H., Takayanagi S., Ishikawa T. Multiple splicing variants of two new human ATP-binding cassette transporters, ABCC11 and ABCC12. Biochem Biophys Res Commun. 2001 Nov 9;288(4):933–939. doi: 10.1006/bbrc.2001.5865. [DOI] [PubMed] [Google Scholar]
  38. Yao S. Y., Ng A. M., Sundaram M., Cass C. E., Baldwin S. A., Young J. D. Transport of antiviral 3'-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Mol Membr Biol. 2001 Apr-Jun;18(2):161–167. doi: 10.1080/09687680110048318. [DOI] [PubMed] [Google Scholar]
  39. Yusa K., Oh-hara T., Yamazaki A., Tsukahara S., Satoh W., Tsuruo T. Cross-resistance to anti-HIV nucleoside analogs in multidrug-resistant human cells. Biochem Biophys Res Commun. 1990 Jun 29;169(3):986–990. doi: 10.1016/0006-291x(90)91991-z. [DOI] [PubMed] [Google Scholar]
  40. Zhang L., Ramratnam B., Tenner-Racz K., He Y., Vesanen M., Lewin S., Talal A., Racz P., Perelson A. S., Korber B. T. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999 May 27;340(21):1605–1613. doi: 10.1056/NEJM199905273402101. [DOI] [PubMed] [Google Scholar]
  41. el-Osta A., Kantharidis P., Zalcberg J. Absolute quantitation of MDR1 transcripts using heterologous DNA standards--validation of the competitive RT-PCR (CRT-PCR) approach. Biotechniques. 1999 Jun;26(6):1114-6, 1118-20, 1122 passim. doi: 10.2144/99266st03. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES